Gadolinium Chelate Complex Purity Control via pH Adjustment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Gadolinium-containing chelate complexes used in magnetic resonance imaging contrast agents often contain toxic impurities like cadmium, mercury, cobalt, lead, and arsenic, which can be genotoxic and cause adverse reactions, particularly in patients with renal insufficiency, due to the instability of these complexes under physiological conditions, leading to the release of free gadolinium ions.
Innovation Solution
A process for preparing liquid parenteral pharmaceutical formulations with reduced toxic impurities involves mixing gadolinium oxide with a chelating agent, adjusting the pH values in specific ranges using the same chelating agent as both a base and an acid, to form stable gadolinium chelate complexes with reduced levels of arsenic, lead, cobalt, cadmium, mercury, and zinc, thereby minimizing the release of free gadolinium ions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If gadolinium oxide is used to produce gadolinium chelate complexes, then the desired contrast agent is formed, but toxic impurities (cadmium, mercury, cobalt, lead, arsenic) are introduced into the formulation
Solution Approach 1:
The patent applies extraction by removing toxic impurities from the gadolinium oxide source material before use. The method selects and uses gadolinium oxide with specifically reduced impurity content, thereby extracting and eliminating the harmful cadmium, mercury, cobalt, lead, and arsenic contaminants from the production process.
Solution Approach 2:
The patent applies parameter changes by specifying precise purity parameters for the gadolinium oxide starting material. It defines maximum acceptable concentrations for various impurities (e.g., cadmium < 10 ppm, mercury < 10 ppm, cobalt < 10 ppm, lead < 10 ppm, arsenic < 10 ppm) and controls the purity of gadolinium oxide to be at least 99.9%, thereby managing toxicity through parameter specification.
2Stability of the object's composition
If zinc impurities are present in gadolinium chelate complexes, then complex formation constants are increased, but gadolinium is displaced from its complexes leading to free gadolinium ions
Solution Approach 1:
The patent applies extraction by removing zinc impurities from the gadolinium oxide source material. It specifies that zinc content in the gadolinium oxide shall be less than 100 ppm, preferably less than 50 ppm, and most preferably less than 10 ppm, thereby eliminating the harmful displacement effect before complex formation occurs.
Solution Approach 2:
The patent applies parameter changes by controlling the zinc content parameter in the gadolinium oxide starting material to specific ranges. By setting maximum zinc concentration limits, the patent prevents transmetallation reactions that would otherwise occur between zinc and the chelating agent.
3Stability of the object's composition
If excess chelating agents are added to prevent gadolinium release, then complex stability is improved, but toxicity increases due to toxic chelating agents themselves
Solution Approach 1:
The patent applies preliminary action by pre-purifying the gadolinium oxide starting material to remove impurities that would cause complex instability. By addressing the root cause (impurity-induced transmetallation) rather than treating the symptom (adding excess chelating agent), the method achieves stability without the harmful side effects of excess reagent.
Solution Approach 2:
The patent converts the potential harm of using gadolinium oxide with mining impurities into a benefit by establishing strict purity specifications. The constraint of limited purity in naturally occurring gadolinium oxide is transformed into a quality control parameter that, when managed properly, ensures safe and stable contrast agent formulation without requiring excess chelating agents.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The process results in formulations with arsenic below 3 ppm, lead and cadmium below 1.5 ppm, mercury below 1 ppm, and zinc below 50 ppm, significantly reducing the risk of adverse reactions and ensuring the stability of gadolinium complexes, making them safer for use as contrast agents in magnetic resonance imaging.
Implementation Method 1
Gadolinium-containing chelate complexes such as Gd-DOTA are typically produced by combining gadolinium oxide (Gd2O3) and a chelating agent in water
Implementation Method 2
adjusting the pH values in specific ranges using the same chelating agent as both a base and an acid
Implementation Method 3
So-called transmetallation reactions appear to play a particularly important role in this process. These transmetallation reactions generally proceed according to the following formula: GdL + M2+ ⇄ Gd3+ + [ML]−
Data Source
AI summary
The present invention relates to a method for producing liquid pharmaceutical formulations suitable for parenteral administration containing gadolinium chelate complexes, in particular gadolinium DOTA, with reduced levels of toxic impurities for use as contrast agents for magnetic resonance imaging.